Hanmi, Beijing Hanmi & Innovent signs co-development partnership of immuno-oncology bispecific antibody
Hanmi Pharm(CEO Sae-Chang Kwon, Jong-Soo Woo) announced on the 30th that it has established a global partnership to jointly develop and commercialize a immune-oncology bispecific antibody with the Chinese biotechnology company Innovent Biologics Co. Ltd.
The bispecific antibody that is jointly b...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
